Efforts to prevent or delay type 1 diabetes have traditionally focused on the autoimmune attack that destroys insulin-producing beta cells. However, emerging research suggests metabolic stress may also influence how quickly vulnerable people progress to clinical disease. A 2026 TrialNet analysis found that autoantibody-positive people with overweight or obesity who …
Read More »Amylin Is Making a Comeback: Why This Forgotten Hormone Is Back in the Spotlight
For years, glucagon-like peptide-1 (GLP-1) receptor agonists have dominated conversations about diabetes and obesity treatment. However, another hormone is quietly returning to the spotlight. Amylin diabetes therapy is making a comeback as researchers develop a new generation of drugs designed to improve blood glucose control and support weight management. Amylin …
Read More »The Glucagon Paradox: Why Activating a “Blood Sugar Hormone” Can Improve Metabolic Health
For decades, glucagon has been viewed as insulin’s opposite. While insulin lowers blood glucose, glucagon raises it by signaling the liver to release stored sugar into the bloodstream. Because of this, glucagon has traditionally been considered a hormone to suppress in people living with type 2 diabetes. However, modern research …
Read More »Protecting Muscle While Treating Obesity: New Protein Targets for Older Adults on GLP-1s
The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are helping patients achieve levels of weight loss that were previously difficult to attain without bariatric surgery. However, as clinicians celebrate these advances, a …
Read More »Monitoring Patients on GLP-1 Therapy: Are We Tracking the Right Outcomes?
As GLP-1 therapies become a long-term cornerstone in diabetes care, monitoring patients on these treatments is gaining renewed attention. Clinicians once focused mainly on A1C and weight, but is that enough today? Much like checking only the speed of a car without looking at fuel or engine health, relying on …
Read More »GLP‑1s for PCOS: From Insulin Resistance to Cycle Control
Could a diabetes medication help women with PCOS regain control of their cycles and metabolism? GLP‑1 receptor agonists, best known for treating type 2 diabetes and obesity, are showing promise for women with polycystic ovary syndrome (PCOS). These medications may support weight loss, improve insulin resistance, and even lead to …
Read More »Reframing Prediabetes: Can Structured Lifestyle Programs Delay or Avoid Medication Use?
Prediabetes affects a striking proportion of adults worldwide, creating a crucial window for intervention before type 2 diabetes develops. While medications like metformin are frequently considered for high-risk individuals, evidence from large clinical trials shows that lifestyle-based strategies — especially the National Diabetes Prevention Program — can dramatically reduce the …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.